What is MOTS-c and how was it discovered?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the 12S ribosomal RNA gene of human mitochondrial DNA — not in nuclear DNA. It was identified by Lee et al. (2015, Cell) using a bioinformatic screen for small open reading frames within mitochondrial RNA that could encode functional peptides. This discovery challenged the long-held assumption that mitochondrial coding capacity was limited to 13 proteins of the oxidative phosphorylation complex. MOTS-c is translated in mitochondria but localizes primarily to the cytoplasm, with translocation to the nucleus under metabolic stress conditions such as glucose deprivation or folate restriction. Its identification opened a new category of mitochondria-derived peptides (MDPs) — small signaling molecules derived from the mitochondrial genome — alongside Humanin, SHLPs, and SHLP6. MOTS-c circulates in human blood at measurable concentrations and declines progressively with aging, supporting its characterization as an endogenous metabolic regulator.

How does MOTS-c activate AMPK and what metabolic effects follow?

MOTS-c activates AMP-activated protein kinase (AMPK) through an indirect mechanism involving the SAICAR (succinylaminoimidazole carboxamide ribotide)-ADSL pathway. Under metabolic stress, MOTS-c modulates the folate cycle and one-carbon metabolism, leading to SAICAR accumulation. SAICAR activates pyruvate kinase M2 and through related metabolic remodeling increases the cellular AMP/ATP ratio — a signal that activates the AMPK heterotrimer by promoting phosphorylation at Thr172 of the alpha subunit. Activated AMPK initiates a metabolic reprogramming cascade: GLUT4 translocation to the plasma membrane increases glucose uptake; phosphorylation of ACC (acetyl-CoA carboxylase) reduces malonyl-CoA and relieves inhibition of CPT1, enabling mitochondrial fatty acid oxidation; PGC-1α upregulation drives mitochondrial biogenesis. In preclinical models, these effects manifest as improved insulin sensitivity in skeletal muscle, reduced adiposity, and enhanced aerobic capacity — the basis for MOTS-c's characterization as an exercise-mimetic peptide.

What does the exercise-mimetic characterization of MOTS-c mean in research terms?

The exercise-mimetic designation reflects the observation that MOTS-c administration in aged rodents recapitulated specific physiological adaptations typically induced by aerobic exercise: improved skeletal muscle glucose uptake, enhanced mitochondrial fatty acid oxidation, increased expression of mitochondrial biogenesis markers (PGC-1α, TFAM), and measurable improvements in grip strength and treadmill capacity. Reynolds et al. (2021, Nature Aging) documented these effects in aged male mice receiving exogenous MOTS-c and reported that circulating MOTS-c itself rises acutely in humans following exercise — suggesting MOTS-c may be part of the endogenous signaling cascade through which exercise communicates systemic metabolic benefits. The exercise-mimetic framing is precise in scope: MOTS-c does not replicate cardiovascular adaptations associated with endurance training, nor the mechanical loading stimulus of resistance exercise. Its characterized effects are specific to AMPK-mediated metabolic substrate utilization and mitochondrial biogenesis — pathways relevant for aging, metabolic disease, and physical performance research.

MOTS-c: Mitochondria-Derived Peptide and Metabolic Regulator

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) has attracted growing research attention as a signaling molecule encoded within the mitochondrial genome rather than the nuclear genome — a distinction that makes it one of the few known mitochondria-derived peptides (MDPs) with systemic metabolic effects. This profile consolidates the published evidence base for MOTS-c, covering its genomic origin, AMPK-dependent mechanism, age-associated plasma dynamics, exercise-mimetic activity in rodent models, and current 503A compounding status.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

Mitochondrial origin and genomic context

Unlike conventional peptides translated from nuclear DNA, MOTS-c is encoded in the mitochondrial 12S ribosomal RNA gene (MT-RNR1). The 16-amino-acid sequence (MRWQEMGYIFYPRKLR) is conserved across mammalian species, a pattern consistent with functional importance. The discovery that mitochondria encode signaling peptides capable of nuclear crosstalk — sometimes called "mitonuclear communication" — has opened a distinct research category separate from classical peptide hormones. Structural conservation and the evolutionary pressure implied by cross-species retention have made MOTS-c a priority target for metabolic and aging research programs.

AMPK activation and insulin-sensitizing mechanism

Preclinical studies, including the landmark 2015 work by Lee and colleagues published in Cell Metabolism, established that MOTS-c reduces insulin resistance in high-fat diet mouse models. The mechanistic pathway involves AMPK (AMP-activated protein kinase) activation, which functions as a cellular energy sensor. Activated AMPK suppresses de novo lipogenesis, promotes glucose uptake, and inhibits the mTORC1 pathway that is frequently hyperactivated in metabolic disease states.

In cell-based models, MOTS-c treatment has been shown to suppress the folate cycle and de novo purine synthesis, resulting in an accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — a naturally occurring AMPK activator. This indirect AMPK activation mechanism distinguishes MOTS-c from pharmacological AMPK agonists and suggests a physiological rather than pharmacological mode of action in the published research.

Age-dependent plasma decline

Circulating MOTS-c concentrations have been reported to decline with age in human cohorts, paralleling the age-associated decline in mitochondrial function broadly. Researchers studying healthy elderly volunteers have observed lower serum MOTS-c compared to younger controls, a finding that has positioned the peptide within longevity-focused preclinical programs alongside other MDPs such as Humanin and SS-31. The age-associated decline is hypothesized to reflect reduced mitochondrial biogenesis and impaired MDP secretion, though the precise regulatory mechanisms governing MOTS-c release into circulation remain under active investigation.

Exercise-mimetic activity in aged rodent models

One of the more discussed findings in the MOTS-c literature involves its pharmacological administration to aged mice. Studies have reported improvements in physical performance metrics — grip strength, running endurance, and muscle insulin sensitivity — in aged rodents administered exogenous MOTS-c. These findings parallel the known AMPK activation observed during aerobic exercise, leading researchers to characterize MOTS-c as a potential "exercise mimetic" at the molecular level.

Importantly, this framing comes exclusively from preclinical rodent data. Phase 1 human data on MOTS-c administration remain limited, and no clinical trials have reported efficacy endpoints. The exercise-mimetic characterization is therefore a mechanistic hypothesis grounded in rodent pharmacology rather than an established human finding.

Relationship to PCOS and insulin resistance research

A 2026 clinical study (PMID 41945630) examined serum MOTS-c levels and the m.1382A>C mitochondrial polymorphism in 121 adolescents diagnosed with polycystic ovary syndrome (PCOS) compared to 125 healthy controls. Serum MOTS-c was marginally elevated in the PCOS group, though the difference did not reach statistical significance (p = 0.059). No significant correlations were identified between MOTS-c concentrations and anthropometric or metabolic parameters within the PCOS cohort. All participants carried the wild-type A/A genotype, precluding polymorphism-dependent analysis.

The study's null findings for this population suggest MOTS-c may play a more limited role in adolescent reproductive metabolic dysfunction than in the aging and skeletal muscle contexts studied preclinically. The contrasting results across research contexts illustrate the importance of population specificity when interpreting the MOTS-c literature.

503A compounding status

Per the FDA's current 503A categorization, MOTS-c is listed as Under Review by the Pharmacy Compounding Advisory Committee (PCAC). This status means MOTS-c has not yet been assigned to Category 1 (eligible for compounding) or Category 2 (ineligible), and its regulatory trajectory remains unresolved pending committee deliberation. Researchers sourcing MOTS-c for laboratory studies should monitor the PCAC review calendar for status updates.

For a full compound profile including molecular formula, molecular weight, and curated study references, see the MOTS-c library profile.

Cited studies

PMID 41945630 — "Are serum MOTS-c levels and MOTS-c m.1382A>C polymorphism related to polycystic ovary syndrome?" (2026). https://doi.org/10.1016/j.cmet.2015.01.013
PMID 25738459 — Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 2015.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.